2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2594

Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Abstract Number: 2595

The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Abstract Number: 2596

Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Abstract Number: 2597

Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
Abstract Number: 2598

The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
Abstract Number: 2599

Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Abstract Number: 2600

Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Abstract Number: 2601

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Abstract Number: 2602

Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Abstract Number: 2603

Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Abstract Number: 2604

The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Abstract Number: 2605

Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
Abstract Number: 2606

Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Abstract Number: 2607

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Intravenous and Subcutaneous Single or Multiple Doses in Healthy Volounters and Subjects with Active SLE
Abstract Number: 2608

Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].